{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T04:30:33Z","timestamp":1750480233886,"version":"3.40.4"},"reference-count":35,"publisher":"Japanese Society of Internal Medicine","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,4,15]]},"DOI":"10.2169\/internalmedicine.3817-24","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T22:10:14Z","timestamp":1725401414000},"page":"1267-1274","source":"Crossref","is-referenced-by-count":2,"title":["Cognitive Dysfunction as an Initial Manifestation of Rheumatoid Arthritis-associated Intravascular Large B-cell Lymphoma"],"prefix":"10.2169","volume":"64","author":[{"given":"Junya","family":"Kitai","sequence":"first","affiliation":[{"name":"Department of General Internal Medicine, Tenri Hospital, Japan"},{"name":"Department of Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuichi","family":"Minoda Sada","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Tenri Hospital, Japan"},{"name":"Department of Transformative Protection to Infectious Disease, Graduate School of Medicine, Osaka University, Japan"},{"name":"Department of Infection Control, Graduate School of Medicine, Osaka University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoko","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tenri Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiyo","family":"Shinde","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tenri Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tenri Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Shimizu Y, Nakajima A, Inoue E, et al. Characteristics and risk factors of lymphoproliferative disorders among patients with rheumatoid arthritis concurrently treated with methotrexate: a nested case-control study of the IORRA cohort. Clin Rheumatol 36: 1237-1245, 2017.","DOI":"10.1007\/s10067-017-3634-5"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Honda S, Sakai R, Inoue E, et al. Association of methotrexate use and lymphoproliferative disorder in patients with rheumatoid arthritis: results from a Japanese multi-institutional retrospective study. Mod Rheumatol 32: 16-23, 2022.","DOI":"10.1080\/14397595.2020.1869370"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Banko A, Miljanovic D, Lazarevic I, et al. New evidence of significant association between EBV presence and lymphoproliferative disorders susceptibility in patients with rheumatoid arthritis: a systematic review with meta-analysis. Viruses 14: 115, 2022.","DOI":"10.3390\/v14010115"},{"key":"4","unstructured":"4. Gaulard P, Swerdlow SH, Harris NL, Sundstrom C, Jaffe ES. Other iatrogenic immunodeficiency-associated lymphoproliferative disorders. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. Swerdlow SH, Campo E, Harris NL, et al., Eds. IARC Press, Lyon, 2017: 462-464."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Tokuhira M, Tamaru JI, Kizaki M. Clinical management for other iatrogenic immunodeficiency-associated lymphoproliferative disorders. J Clin Exp Hematop 59: 72-92, 2019.","DOI":"10.3960\/jslrt.19007"},{"key":"6","unstructured":"6. Hoshida Y, Xu JX, Fujita S, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol 34: 322-331, 2007."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Saito R, Tanaka M, Ito H, et al. Overall survival and post-spontaneous regression relapse-free survival of patients with lymphoproliferative disorders associated with rheumatoid arthritis: a multi-center retrospective cohort study. Mod Rheumatol 32: 50-58, 2022.","DOI":"10.1080\/14397595.2020.1866837"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Tokuhira M, Watanabe R, Nemoto T, et al. Clinicopathological analyses in patients with other iatrogenic immunodeficiency-associated lymphoproliferative diseases and rheumatoid arthritis. Leuk Lymphoma 53: 616-623, 2012.","DOI":"10.3109\/10428194.2011.625101"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Takada H, Kaneko Y, Nakano K, et al. Clinicopathological characteristics of lymphoproliferative disorders in 232 patients with rheumatoid arthritis in Japan: a retrospective, multicenter, descriptive study. Mod Rheumatol 32: 32-40, 2022.","DOI":"10.1080\/14397595.2021.1899570"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kurita D, Miyoshi H, Ichikawa A, et al. Methotrexate-associated lymphoproliferative disorders in patients with rheumatoid arthritis: clinicopathologic features and prognostic factors. Am J Surg Pathol 43: 869-884, 2019.","DOI":"10.1097\/PAS.0000000000001271"},{"key":"11","unstructured":"11. Pfleger L, Tappeiner J. [On the recognition of systematized endotheliomatosis of the cutaneous blood vessels (reticuloendotheliosis?]. Hautarzt 10: 359-363, 1959 (in German)."},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Ponzoni M, Campo E, Nakamura S. Intravascular large B-cell lymphoma: a chameleon with multiple faces and many masks. Blood 132: 1561-1567, 2018.","DOI":"10.1182\/blood-2017-04-737445"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Murase T, Nakamura S, Kawauchi K, et al. An Asian variant of intravascular large B-cell lymphoma: clinical, pathological and cytogenetic approaches to diffuse large B-cell lymphoma associated with haemophagocytic syndrome. Br J Haematol 111: 826-834, 2000.","DOI":"10.1111\/j.1365-2141.2000.02426.x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Ferreri AJ, Campo E, Seymour JF, et al. Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'. Br J Haematol 127: 173-183, 2004.","DOI":"10.1111\/j.1365-2141.2004.05177.x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Shimada K, Kiyoi H. Current progress and future perspectives of research on intravascular large B-cell lymphoma. Cancer Sci 112: 3953-3961, 2021.","DOI":"10.1111\/cas.15091"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Shimada K, Matsue K, Yamamoto K, et al. Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. J Clin Oncol 26: 3189-3195, 2008.","DOI":"10.1200\/JCO.2007.15.4278"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Ferreri AJ, Dognini GP, Bairey O, et al. The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in 'Western' patients with intravascular large B-cell lymphoma. Br J Haematol 143: 253-257, 2008.","DOI":"10.1111\/j.1365-2141.2008.07338.x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Shimada K, Yamaguchi M, Atsuta Y, et al. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial. Lancet Oncol 21: 593-602, 2020.","DOI":"10.1016\/S1470-2045(20)30059-0"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kuramoto N, Saito S, Fujii T, et al. Characteristics of rheumatoid arthritis with immunodeficiency-associated lymphoproliferative disorders to regress spontaneously by the withdrawal of methotrexate and their clinical course: a retrospective, multicenter, case-control study. Mod Rheumatol 32: 24-31, 2022.","DOI":"10.1080\/14397595.2021.1879362"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Fonkem E, Dayawansa S, Stroberg E, et al. Neurological presentations of intravascular lymphoma (IVL): meta-analysis of 654 patients. BMC Neurol 16: 9, 2016.","DOI":"10.1186\/s12883-015-0509-8"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Abe Y, Narita K, Kobayashi H, et al. Clinical value of abnormal findings on brain magnetic resonance imaging in patients with intravascular large B-cell lymphoma. Ann Hematol 97: 2345-2352, 2018.","DOI":"10.1007\/s00277-018-3481-8"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Willemze R, Kruyswijk MR, De Bruin CD, Meijer CJ, Van Berkel W. Angiotropic (intravascular) large cell lymphoma of the skin previously classified as malignant angioendotheliomatosis. Br J Dermatol 116: 393-399, 1987.","DOI":"10.1111\/j.1365-2133.1987.tb05854.x"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Kikuchi J, Kaneko Y, Kasahara H, et al. Methotrexate-associated intravascular large B-cell lymphoma in a patient with rheumatoid arthritis. Intern Med 55: 1661-1665, 2016.","DOI":"10.2169\/internalmedicine.55.6943"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Kida T, Kohno M, Chinen Y, et al. Intravascular lymphoma in a rheumatoid arthritis patient following short-term methotrexate treatment. Rheumatology (Oxford) 56: 318-320, 2017.","DOI":"10.1093\/rheumatology\/kew414"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Hagihara M, Mese T, Ohara S, Hua J, Ide S, Inoue M. Methotrexate-associated intravascular large B-cell lymphoma in a patient with rheumatoid arthritis: a very rare case. Intern Med 57: 3001-3005, 2018.","DOI":"10.2169\/internalmedicine.0875-18"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Iwami E, Ito F, Sasahara K, et al. Pulmonary intravascular large B-cell lymphoma in a patient administered methotrexate for rheumatoid arthritis. Intern Med 59: 429-433, 2020.","DOI":"10.2169\/internalmedicine.3216-19"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Tabuchi T, Inoue H, Obama K. Development of intravascular large B-cell lymphoma during methotrexate treatment for rheumatoid arthritis. Intern Med 61: 87-90, 2022.","DOI":"10.2169\/internalmedicine.7531-21"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Bogomolski-Yahalom V, Lossos IS, Okun E, Sherman Y, Lossos A, Polliack A. Intravascular lymphomatosis - an indolent or aggressive entity? Leuk Lymphoma 29: 585-593, 1998.","DOI":"10.3109\/10428199809050918"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Komeno Y, Akiyama M, Okochi Y, et al. Hemophagocytic syndrome-associated intravascular large B-cell lymphoma in a rheumatoid arthritis patient. Case Rep Hematol 2019: 8947616, 2019.","DOI":"10.1155\/2019\/8947616"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Chakravarty K, Goyal M, Scott DG, McCann BG. Malignant 'angioendotheliomatosis'- (intravascular lymphomatosis) an unusual cutaneous lymphoma in rheumatoid arthritis. Br J Rheumatol 32: 932-934, 1993.","DOI":"10.1093\/rheumatology\/32.10.932"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Winegarner A, Hashida N, Koh S, Nishida K. Hemorrhagic hypopyon as presenting feature of intravascular lymphoma, a case report. BMC Ophthalmol 17: 195, 2017.","DOI":"10.1186\/s12886-017-0591-3"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. W\u00f6hrer S, Troch M, Zwerina J, et al. Influence of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone on serologic parameters and clinical course in lymphoma patients with autoimmune diseases. Ann Oncol 18: 647-651, 2007.","DOI":"10.1093\/annonc\/mdl467"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Wang KC, Liao HT, Chen WS, et al. Real-world effectiveness and safety of rituximab in the treatment of rheumatoid arthritis: a single-center experience in Taiwan. Int. J. Rheum. Dis 22: 860-868, 2019.","DOI":"10.1111\/1756-185X.13511"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350: 2572-2581, 2004.","DOI":"10.1056\/NEJMoa032534"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54: 1390-1400, 2006.","DOI":"10.1002\/art.21778"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/8\/64_3817-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T03:30:23Z","timestamp":1745033423000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/8\/64_3817-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3817-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"type":"print","value":"0918-2918"},{"type":"electronic","value":"1349-7235"}],"subject":[],"published":{"date-parts":[[2025,4,15]]},"article-number":"3817-24"}}